GPD1

Across TCGA pan-cancer cohorts, GPD1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GPD1 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GPD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GPD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where GPD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.651	0.399	<.001	60	view →
LUAD	DFS	Quartile	III,IV	0.332	0.846	.008	27	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.689	.016	17	view →
GBM	OS	Tertile	All	0.407	0.669	.001	14	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	DFS	Tertile	All	0.861	1.000	.015	6	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GPD1–PDAC (OS)

Open the PDAC breakdown →